Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis.
G. vaginalis
Autodock Vina
GROMACS
Vaginosis
Virtual screening
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
20
05
2024
accepted:
23
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
epublish
Résumé
Bacterial vaginosis (BV), primarily attributed to Gardnerella vaginalis, poses significant challenges due to antibiotic resistance and suboptimal treatment outcomes. This study presents an integrated approach to identify potential drug targets and screen compounds against this bacterium by leveraging a computational methodology. Subtractive proteomics of the reference strain ASM286196v1/UMB0386 (assembly accession: GCA_002861965.1) facilitated the prioritization of proteins with essential bacterial functions and pathways as potential drug targets. We selected 3-deoxy-7-phosphoheptulonate synthase (aroG gene product; also known as DAHP synthase) for downstream analysis. Molecular docking was employed in PyRx (AutoDock Vina) to predict binding affinities between aroG inhibitors from the ZINC database and 3-deoxy-7-phosphoheptulonate synthase. Molecular dynamics simulations of 100 ns, using GROMACS, validated the stability of drug-target interactions. Additionally, ADMET profiling aided in the selection of compounds with favorable pharmacokinetic properties and safety profile for human hosts. PBPK profiling showed that ZINC98088375 had the highest bioavailability and efficient systemic circulation. Conversely, ZINC5113880 demonstrated the lowest absorption rate (39.661%). Moreover, cirrhosis, steatosis, and renal impairment appeared to influence blood concentration of the drug, impacting bioavailability. The integrative -omics approach utilized in this study underscores the potential of computer-aided drug design and offers a rational strategy for targeted inhibitor discovery against G. vaginalis. The strategy is an attempt to address the limitations of current BV treatments, including antibiotic resistance, and pave way for the development of safer and more effective therapeutics.
Identifiants
pubmed: 39075099
doi: 10.1038/s41598-024-68443-2
pii: 10.1038/s41598-024-68443-2
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17437Informations de copyright
© 2024. The Author(s).
Références
Bitew, A., Mengist, A., Belew, H., Aschale, Y. & Reta, A. The prevalence, antibiotic resistance pattern, and associated factors of bacterial vaginosis among women of the reproductive age group from felege hiwot referral hospital, Ethiopia. Infect. Drug Resist. 5, 2685–2696 (2021).
doi: 10.2147/IDR.S305329
Schellenberg, J. J., Patterson, M. H. & Hill, J. E. Gardnerella vaginalis diversity and ecology in relation to vaginal symptoms. Res. Microbiol. 168, 837–844 (2017).
pubmed: 28341009
doi: 10.1016/j.resmic.2017.02.011
Qin, H. & Xiao, B. Research progress on the correlation between Gardnerella typing and bacterial vaginosis. Front. Cell. Infect. Microbiol. 12, 858155 (2022).
pubmed: 35402309
pmcid: 8990036
doi: 10.3389/fcimb.2022.858155
Ma, X. et al. Biofilm and pathogenic factor analysis of Gardnerella vaginalis associated with bacterial vaginosis in Northeast China. Front. Microbiol. 13, 1033040 (2022).
pubmed: 36619994
pmcid: 9815022
doi: 10.3389/fmicb.2022.1033040
Bhujel, R., Mishra, S. K., Yadav, S. K., Bista, K. D. & Parajuli, K. Comparative study of Amsel’s criteria and Nugent scoring for diagnosis of bacterial vaginosis in a tertiary care hospital, Nepal. BMC Infect. Dis. 21, 1–6 (2021).
doi: 10.1186/s12879-021-06562-1
Nenadić, D. B., Pavlović, M. D. & Motrenko, T. A novel microscopic method for analyzing Gram-stained vaginal smears in the diagnosis of disorders of vaginal microflora. Vojnosanit. Pregl. 72, 670–676 (2015).
pubmed: 26495692
doi: 10.2298/VSP140612065N
Numanović, F. et al. Importance of isolation and biotypization of Gardnerella vaginalis in diagnosis of bacterial vaginosis. Bosn. J. Basic Med. Sci. 8, 270 (2008).
pubmed: 18816262
pmcid: 5694681
doi: 10.17305/bjbms.2008.2932
Redelinghuys, M. J., Geldenhuys, J., Jung, H. & Kock, M. M. J. Bacterial vaginosis: Current diagnostic avenues and future opportunities. Front. Cell. Infect. Microbiol. 10, 354 (2020).
pubmed: 32850469
pmcid: 7431474
doi: 10.3389/fcimb.2020.00354
Janulaitiene, M. et al. Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis. BMC Infect. Dis. 17, 1–9 (2017).
doi: 10.1186/s12879-017-2501-y
Pleckaityte, M. Cholesterol-dependent cytolysins produced by vaginal bacteria: Certainties and controversies. Front. Cell. Infect. Microbiol. 9, 452 (2020).
pubmed: 31998661
pmcid: 6966277
doi: 10.3389/fcimb.2019.00452
Hardy, L. et al. The presence of the putative Gardnerella vaginalis sialidase A gene in vaginal specimens is associated with bacterial vaginosis biofilm. PLoS ONE 12, e0172522 (2017).
pubmed: 28241058
pmcid: 5328246
doi: 10.1371/journal.pone.0172522
Abbe, C. & Mitchell, C. M. Bacterial vaginosis: A review of approaches to treatment and prevention. Front. Reprod. Health 5, 1100029 (2023).
pubmed: 37325243
pmcid: 10264601
doi: 10.3389/frph.2023.1100029
Wu, S., Hugerth, L. W., Schuppe-Koistinen, I. & Du, J. The right bug in the right place: opportunities for bacterial vaginosis treatment. npj Biofilms Microbiomes 8, 34 (2022).
Munoz-Barreno, A., Cabezas-Mera, F., Tejera, E. & Machado, A. Comparative effectiveness of treatments for bacterial vaginosis: A network meta-analysis. Antibiotics 10, 978 (2021).
pubmed: 34439028
pmcid: 8388924
doi: 10.3390/antibiotics10080978
Owens, D. K. et al. Screening for bacterial vaginosis in pregnant persons to prevent preterm delivery: US preventive services task force recommendation statement. Jama 323, 1286–1292 (2020).
pubmed: 32259236
doi: 10.1001/jama.2020.2684
Bradshaw, C. S. & Sobel, J. D. Current treatment of bacterial vaginosis—Limitations and need for innovation. J. Infect. Dis. 214, S14–S20 (2016).
pubmed: 27449869
pmcid: 4957510
doi: 10.1093/infdis/jiw159
Alturki, N. A. et al. Therapeutic target identification and inhibitor screening against riboflavin synthase of colorectal cancer associated fusobacterium nucleatum. Cancers 14, 6260 (2022).
pubmed: 36551744
pmcid: 9777469
doi: 10.3390/cancers14246260
Sinoliya, P., Solanki, P. S., Niraj, R. R. K. & Sharma, V. Computational study of antimicrobial peptides for promising therapeutic applications against methicillin-resistant Staphylococcus aureus. Curr. Comput. Aided Drug Des. https://doi.org/10.2174/0115734099285473240101111303 (2024).
doi: 10.2174/0115734099285473240101111303
pubmed: 38231068
Sinoliya, P., Solanki, P. S., Piplani, S., Kumar Niraj, R. R. & Sharma, V. Anti-microbial peptides against methicillin-resistant Staphylococcus aureus: Promising therapeutics. Curr. Protein Pept. Sci. 24, 156–177. https://doi.org/10.2174/1389203724666221216115850 (2023).
doi: 10.2174/1389203724666221216115850
pubmed: 36529917
Gupta, S. R. et al. Comparative proteome analysis of Mycobacterium tuberculosis strains-H37Ra, H37Rv, CCDC5180, and CAS/NITR204: A step forward to identify novel drug targets. Lett. Drug Des. Discov. 17, 1422–1431 (2020).
doi: 10.2174/1570180817999200531165148
Zaidi, S., Bhardwaj, T., Somvanshi, P. & Khan, A. U. Proteomic characterization and target identification against Streptococcus mutans under bacitracin stress conditions using LC–MS and subtractive proteomics. Protein J. 41, 166–178 (2022).
pubmed: 34989956
pmcid: 8733428
doi: 10.1007/s10930-021-10038-1
Öztürk, H., Özgür, A. & Ozkirimli, E. DeepDTA: Deep drug-target binding affinity prediction. Bioinformatics 34, i821–i829 (2018).
pubmed: 30423097
pmcid: 6129291
doi: 10.1093/bioinformatics/bty593
Alzamami, A., Alturki, N. A., Khan, K., Basharat, Z. & Mashraqi, M. M. Screening inhibitors against the Ef-Tu of Fusobacterium nucleatum: A docking, ADMET and PBPK assessment study. Mol. Divers. 1–18 (2024).
Korf, I., Yandell, M. & Bedell, J. Blast. (O'Reilly Media, Inc., 2003).
Liu, S. et al. CEG 2.0: An updated database of clusters of essential genes including eukaryotic organisms. Database 2020, baaa112 (2020).
pubmed: 33306800
pmcid: 7731928
doi: 10.1093/database/baaa112
Zhang, R., Ou, H. Y. & Zhang, C. T. DEG: A database of essential genes. Nucleic Acids Res. 32, D271–D272 (2004).
pubmed: 14681410
pmcid: 308758
doi: 10.1093/nar/gkh024
Basharat, Z., Jahanzaib, M., Yasmin, A. & Khan, I. A. Pan-genomics, drug candidate mining and ADMET profiling of natural product inhibitors screened against Yersinia pseudotuberculosis. Genomics 113, 238–244 (2021).
pubmed: 33321204
doi: 10.1016/j.ygeno.2020.12.015
Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).
pubmed: 29126136
doi: 10.1093/nar/gkx1037
Grasso, D., Galderisi, S., Santucci, A. & Bernini, A. Pharmacological chaperones and protein conformational diseases: Approaches of computational structural biology. Int. J. Mol. Sci. 24, 5819 (2023).
pubmed: 36982893
pmcid: 10054308
doi: 10.3390/ijms24065819
Bull, S. C. & Doig, A. J. Properties of protein drug target classes. PloS one 10, e0117955 (2015).
pubmed: 25822509
pmcid: 4379170
doi: 10.1371/journal.pone.0117955
Gasteiger, E. et al. Protein Identification and Analysis Tools on the ExPASy Server. (Humana Press, 2005).
Hallgren, J. et al. DeepTMHMM predicts alpha and beta transmembrane proteins using deep neural networks. BioRxiv: 2022.2004.2008.487609 (2022).
Saha, S. & Raghava, G. P. BTXpred: Prediction of bacterial toxins. In Silico Biol. 7, 405–412 (2007).
pubmed: 18391233
Sharma, N. et al. AlgPred 2.0: An improved method for predicting allergenic proteins and mapping of IgE epitopes. Brief. Bioinform. 22, 294 (2021).
doi: 10.1093/bib/bbaa294
Kiefer, F., Arnold, K., Künzli, M., Bordoli, L. & Schwede, T. The SWISS-MODEL repository and associated resources. Nucleic Acids Res. 37, D387–D392 (2009).
pubmed: 18931379
doi: 10.1093/nar/gkn750
Bæk, K. T. & Kepp, K. P. Assessment of AlphaFold2 for human proteins via residue solvent exposure. J. Chem. Inf. Model. 62, 3391–3400 (2022).
pubmed: 35785970
doi: 10.1021/acs.jcim.2c00243
Schwede, T., Kopp, J., Guex, N. & Peitsch, M. C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381–3385 (2003).
pubmed: 12824332
pmcid: 168927
doi: 10.1093/nar/gkg520
Perrakis, A. & Sixma, T. K. AI revolutions in biology: The joys and perils of AlphaFold. EMBO Rep. 22, e54046 (2021).
pubmed: 34668287
pmcid: 8567224
doi: 10.15252/embr.202154046
Mirdita, M. et al. ColabFold: Making protein folding accessible to all. Nat. Methods 19, 679–682 (2022).
pubmed: 35637307
pmcid: 9184281
doi: 10.1038/s41592-022-01488-1
Heo, L., Park, H. & Seok, C. GalaxyRefine: Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 41, W384–W388 (2013).
pubmed: 23737448
pmcid: 3692086
doi: 10.1093/nar/gkt458
Laskowski, R. A. et al. PDBsum: A web-based database of summaries and analyses of all PDB structures. Trends Biochem. Sci. 22, 488–490 (1997).
pubmed: 9433130
doi: 10.1016/S0968-0004(97)01140-7
Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Chem. Biol. Methods Protoc. 243–250 (2015).
Sireesha, R. et al. Unveiling the anticancer mechanism of 1, 2, 3-triazole-incorporated thiazole-pyrimidine-isoxazoles: Insights from docking and molecular dynamics simulations. J. Biomol. Struct. Dyn. 1–13 (2023).
Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand–protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786 (2011).
pubmed: 21919503
doi: 10.1021/ci200227u
Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).
pubmed: 28256516
pmcid: 5335600
doi: 10.1038/srep42717
Pires, D. E., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066–4072 (2015).
pubmed: 25860834
pmcid: 4434528
doi: 10.1021/acs.jmedchem.5b00104
Ertl, P. & Schuffenhauer, A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J. Cheminform. 1, 1–11 (2009).
doi: 10.1186/1758-2946-1-8
Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J. Comput. Chem. 26, 1701–1718 (2005).
pubmed: 16211538
doi: 10.1002/jcc.20291
Huai, Z., Shen, Z. & Sun, Z. Binding thermodynamics and interaction patterns of inhibitor-major urinary protein-I binding from extensive free-energy calculations: Benchmarking AMBER force fields. J. Chem. Inf. Model. 61, 284–297 (2020).
pubmed: 33307679
doi: 10.1021/acs.jcim.0c01217
Eskandari, A., Leow, T. C., Rahman, M. B. A. & Oslan, S. N. Molecular dynamics-guided insight into the adsorption–inhibition mechanism for controlling ice growth/melt of antifreeze protein type IV mutant from longhorn sculpin fish. Chem. Pap. 1–18 (2024).
Wang, E. et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chem. Rev. 119, 9478–9508 (2019).
pubmed: 31244000
doi: 10.1021/acs.chemrev.9b00055
Yokoyama, R., Kleven, B., Gupta, A., Wang, Y. & Maeda, H. A. 3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase as the gatekeeper of plant aromatic natural product biosynthesis. Curr. Opin. Plant Biol. 67, 102219 (2022).
pubmed: 35550985
doi: 10.1016/j.pbi.2022.102219
Liu, S., Xu, J.-Z. & Zhang, W.-G. Advances and prospects in metabolic engineering of Escherichia coli for l-tryptophan production. World J. Microbiol. Biotechnol. 38, 22 (2022).
pubmed: 34989926
doi: 10.1007/s11274-021-03212-1
Singh, P. et al. Biofuel from Microbes and Plants. 189–209 (CRC Press, 2021).
Almeida, A. M. et al. Revisiting the Shikimate Pathway and Highlighting Their Enzyme Inhibitors. 1–37 (2023).
Castro, J. I. R. Adhesion of Vaginal Microorganisms to Epithelial Cells and Its Association with Bacterial Vaginosis. (Universidade do Minho (Portugal), 2012).
Anton, L. et al. Gardnerella vaginalis alters cervicovaginal epithelial cell function through microbe-specific immune responses. Microbiome 10, 119 (2022).
pubmed: 35922830
pmcid: 9351251
doi: 10.1186/s40168-022-01317-9
Niu, A. Toward Transition State Analysis of DAHP Synthase (2020).
Jeckelmann, J.-M. & Erni, B. Carbohydrate transport by group translocation: the bacterial phosphoenolpyruvate: Sugar phosphotransferase system. In Bacterial Cell Walls Membranes. 223–274 (2019).
Agoni, C., Olotu, F. A., Ramharack, P. & Soliman, M. E. Druggability and drug-likeness concepts in drug design: Are biomodelling and predictive tools having their say?. J. Mol. Model. 26, 1–11 (2020).
doi: 10.1007/s00894-020-04385-6
Amabebe, E. & Anumba, D. O. Mechanistic insights into immune suppression and evasion in bacterial vaginosis. Curr. Microbiol. 79, 84 (2022).
pubmed: 35128579
pmcid: 8818625
doi: 10.1007/s00284-022-02771-2
Wong, Y. P. et al. Gardnerella vaginalis infection in pregnancy: Effects on placental development and neonatal outcomes. Placenta 120, 79–87 (2022).
pubmed: 35231793
doi: 10.1016/j.placenta.2022.02.018
Daskalakis, G. et al. Maternal infection and preterm birth: from molecular basis to clinical implications. Children 10, 907 (2023).
pubmed: 37238455
pmcid: 10217143
doi: 10.3390/children10050907
Menard, J.-P. Antibacterial treatment of bacterial vaginosis: Current and emerging therapies. Int. J. Women's Health 295–305 (2011).
Owen, M. K. & Clenney, T. L. Management of vaginitis. Am. Fam. Phys. 70, 2125–2132 (2004).
Pentikis, H., Adetoro, N., Tipping, D. & Levy, S. An integrated efficacy and safety analysis of single-dose secnidazole 2 g in the treatment of bacterial vaginosis. Reprod. Sci. 27, 523–528 (2020).
pubmed: 32046418
doi: 10.1007/s43032-019-00048-x
Al-Kraety, I. A. A., Al-Muhanna, S. G., Banoon, S. R. & Ghasemian, A. Bacterial vaginosis pattern and antibiotic susceptibility testing in female patients using high vaginal swabs. Biodivers. J. Biol. Divers. 23, 34 (2022).
doi: 10.13057/biodiv/d230608
Qian, Z., Zhao, D., Yin, Y., Zhu, H. & Chen, D. Antibacterial activity of Lactobacillus strains isolated from Mongolian yogurt against Gardnerella vaginalis. BioMed Res. Int. 2020 (2020).
Ahmad, S. S. & Ali, F. A. Detection of ESBL, AmpC and metallo beta-lactamase mediated resistance in Gram-negative bacteria isolated from women with genital tract infection. Eur. Sci. J. 10 (2014).
Wang, S., Liu, D., Bilal, M., Wang, W. & Zhang, X. Uncovering the role of phzc as DAHP synthase in shikimate pathway of Pseudomonas chlororaphis HT66. Biology 11, 86 (2022).
pubmed: 35053084
pmcid: 8772962
doi: 10.3390/biology11010086
Tohge, T. & R Fernie, A. An overview of compounds derived from the shikimate and phenylpropanoid pathways and their medicinal importance. Mini Rev. Med. Chem. 17, 1013–1027 (2017).
Almeida, A. M. et al. Revisiting the shikimate pathway and highlighting their enzyme inhibitors. Phytochem. Rev. 1–37 (2023).
Dev, A., Tapas, S., Pratap, S. & Kumar, P. Structure and function of enzymes of shikimate pathway. Curr. Bioinform. 7, 374–391 (2012).
doi: 10.2174/157489312803900983
Shumilin, I. A., Bauerle, R., Wu, J., Woodard, R. W. & Kretsinger, R. H. Crystal structure of the reaction complex of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Thermotoga maritima refines the catalytic mechanism and indicates a new mechanism of allosteric regulation. J. Mol. Biol. 341, 455–466 (2004).
pubmed: 15276836
doi: 10.1016/j.jmb.2004.05.077
Cui, D. et al. Molecular basis for feedback inhibition of tyrosine-regulated 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase from Escherichia coli. J. Struct. Biol. 206, 322–334 (2019).
pubmed: 30946901
doi: 10.1016/j.jsb.2019.04.001
Balachandran, N. et al. Potent inhibition of 3-deoxy-D-arabinoheptulosonate-7-phosphate (DAHP) synthase by DAHP oxime, a phosphate group mimic. Biochemistry 55, 6617–6629 (2016).
pubmed: 27933795
doi: 10.1021/acs.biochem.6b00930
de Oliveira, M. D., Araujo, J. D. O., Galúcio, J. M., Santana, K. & Lima, A. H. Targeting shikimate pathway: In silico analysis of phosphoenolpyruvate derivatives as inhibitors of EPSP synthase and DAHP synthase. J. Mol. Graph. Model. 101, 107735 (2020).
pubmed: 32947107
doi: 10.1016/j.jmgm.2020.107735
Stegemann, S., Leveiller, F., Franchi, D., De Jong, H. & Lindén, H. When poor solubility becomes an issue: From early stage to proof of concept. Eur. J. Pharmaceut. Sci. 31, 249–261 (2007).
doi: 10.1016/j.ejps.2007.05.110
Fang, Y. Ligand–receptor interaction platforms and their applications for drug discovery. Exp. Opin. Drug Discov. 7, 969–988 (2012).
doi: 10.1517/17460441.2012.715631
He, J. et al. Binding properties of the natural red dye carthamin with human serum albumin: Surface plasmon resonance, isothermal titration microcalorimetry, and molecular docking analysis. Food Chem. 221, 650–656 (2017).
pubmed: 27979254
doi: 10.1016/j.foodchem.2016.11.124
Kairys, V., Baranauskiene, L., Kazlauskiene, M., Matulis, D. & Kazlauskas, E. Binding affinity in drug design: Experimental and computational techniques. Expert Opin Drug Discov. 14, 755–768 (2019).
pubmed: 31146609
doi: 10.1080/17460441.2019.1623202
Taskar, K. S., Harada, I. & Alluri, R. V. Physiologically-based pharmacokinetic (PBPK) modelling of transporter mediated drug absorption, clearance and drug–drug interactions. Curr. Drug Metab. 22, 523–531 (2021).
pubmed: 33397250
doi: 10.2174/1389200221999210101233340
Alrubia, S., Mao, J., Chen, Y., Barber, J. & Rostami-Hodjegan, A. Altered bioavailability and pharmacokinetics in Crohn’s disease: Capturing systems parameters for PBPK to assist with predicting the fate of orally administered drugs. Clin. Pharmacokinet. 61, 1365–1392 (2022).
pubmed: 36056298
pmcid: 9553790
doi: 10.1007/s40262-022-01169-4
Hartmanshenn, C., Scherholz, M. & Androulakis, I. P. Physiologically-based pharmacokinetic models: Approaches for enabling personalized medicine. J. Pharmacokinet. Pharmacodyn. 43, 481–504 (2016).
pubmed: 27647273
pmcid: 5204363
doi: 10.1007/s10928-016-9492-y
Rowland Yeo, K., Aarabi, M., Jamei, M. & Rostami-Hodjegan, A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev. Clin. Pharmacol. 4, 261–274 (2011).
pubmed: 22115405
doi: 10.1586/ecp.10.143